Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gensight BiologicsGSGTF -100.00%2 3-Year EPS without NRI Growth Rate is 47.30% as of Dec. 2025, which is 401% above its 10-year median of 9.45. GuruFocus rates GSGTF with a GF Score™ of 2/100 and a GF Value™ of $0.04 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,157 Biotechnology companies, Gensight Biologics ranks better than 83.58% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 47.30% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 33.50% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 19.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Gensight Biologics was 47.30% per year. The lowest was -86.70% per year. And the median was 9.45% per year.
Gensight Biologics (OTCPK:GSGTF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Gensight Biologics 3-Year EPS without NRI Growth Rate Related Terms
GSGTF vs VRTX, REGN, MRNA: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Gensight Biologics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gensight Biologics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gensight Biologics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Gensight Biologics's 3-Year EPS without NRI Growth Rate falls into.
Gensight Biologics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 47.30% mean?
Gensight Biologics (GSGTF) has a 3-Year EPS without NRI Growth Rate of 47.30% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Gensight Biologics and its competitors. This is 401% above median its historical median of 9.45. According to the industry distribution chart, Gensight Biologics ranks #190 out of 1157 companies in the Biotechnology industry, placing it in the top 16.4%.
Is Gensight Biologics' 3-Year EPS without NRI Growth Rate too high?
Gensight Biologics' current 3-Year EPS without NRI Growth Rate of 47.30% is 401% above median its 10-year median of 9.45. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 15.90. Gensight Biologics' value of 47.30% is 197.5% above this industry median. Based on the distribution chart, Gensight Biologics ranks #190 out of 1157 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gensight Biologics has a GF Score™ of 2/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gensight Biologics' 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gensight Biologics ranks #190 out of 1157 companies for 3-Year EPS without NRI Growth Rate. This places Gensight Biologics in the top 16% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 15.90. Gensight Biologics' value of 47.30% is 197.5% above this benchmark. While the company's 10-year median is 9.45 vs. the industry median of 15.90, Gensight Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 15.90, based on 1,157 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gensight Biologics's current 3-Year EPS without NRI Growth Rate of 47.30% is 197.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Gensight Biologics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gensight Biologics's current 3-Year EPS without NRI Growth Rate is 47.30%, which is 401% above median its own 10-year median of 9.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (GSGTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.04, compared to a current price of $0.09 — trading 125% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 47.30%, which is 401% above median its 10-year median of 9.45 and 197.5% above the Biotechnology industry median of 15.90. Gensight Biologics' overall GF Score™ is 2/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Gensight Biologics (GSGTF), the current 3-Year EPS without NRI Growth Rate is 47.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gensight Biologics (GSGTF) Overvalued in 2026?
Based on GuruFocus' analysis, Gensight Biologics stock appears to be overvalued.
The current stock price of $0.09 is trading 125% above its estimated GF Value™ of $0.04.
GuruFocus considers Gensight Biologics to be Significantly Overvalued.
Key valuation signals for GSGTF:
3-Year EPS without NRI Growth Rate: 47.30% (401% above median its 10-year median of 9.45)
GF Value™: $0.04 vs. price of $0.09 (125% above fair value)
Industry Position: 197.5% above the Biotechnology median (#190 of 1157)
No single metric tells the full story. See the GSGTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
2GF Score
Get the complete analysis for GSGTF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GSGTF has been successfully added to your 
